This open-label, multicenter, non-randomized study will provide continued access to vemurafenib for eligible patients with BRAF V600 mutation-positive malignancy, who were previously enrolled and treated in an antecedent vemurafenib protocol and did not meet the protocol's criteria for disease progression, or are treated beyond progression and are still deriving clinical benefit (as assessed by investigator), and may therefore potentially benefit from continued treatment with vemurafenib. Patients will receive treatment with vemurafenib 960 mg orally twice daily or, if the dose was reduced in an antecedent protocol, the dose of the last visit of the antecedent study (minimum 480 mg orally twice daily). Treatment will continue until progression of disease or as long as the patient is deriving clinical benefit, as judged by the investigator, or until unacceptable toxicity occurs.
*For Eligibility information, look up the trial at NIH by clicking on the Study Number above.*
Other eligibility criteria may apply.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
If you are considering taking part in a clinical trial, talk with your SCCA team about the pros and cons. Discuss what you learn with your health care providers, family and trusted friends. See also the Patient Guide to Clinical Trials.